Drug treatment for multidrug-resistant Acinetobacter baumannii infections

摘要

Acinetobacter baumannii has emerged in the last decades as a major cause ofnhealthcare-associated infections and nosocomial outbreaks. Multidrug-resistantn(MDR) A. baumannii is a rapidly emerging pathogen in healthcare settings, wherenit causes infections that include bacteremia, pneumonia, meningitis, and urinaryntract and wound infections. Antimicrobial resistance poses great limits forntherapeutic options in infected patients, especially if the isolates are resistant tonthe carbapenems. Other therapeutic options include sulbactam, aminoglycosides,npolymixyns and tigecycline. The discovery of new therapies coupled with thendevelopment of controlled clinical trial antibiotic testing combinations and thenprevention of transmission of MDR Acinetobacter infection are essential to facenthis important hospital problem.